Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 821592, 5 pages
http://dx.doi.org/10.1155/2008/821592
Review Article

PPAR- 𝜶 Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration

The Wilmer Ophthalmological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD 21287-9278, USA

Received 1 November 2007; Revised 24 January 2008; Accepted 19 February 2008

Academic Editor: Suofu Qin

Copyright © 2008 Marisol del V Cano and Peter L. Gehlbach. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Klein, B. E. Klein, and K. L. Linton, “Prevalence of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 99, no. 6, pp. 933–943, 1992. View at Google Scholar
  2. F. Kinose, G. Roscilli, S. Lamartina et al., “Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor,” Molecular Vision, vol. 11, pp. 366–373, 2005. View at Google Scholar
  3. B. Muñoz, S. K. West, G. S. Rubin et al., “Causes of blindness and visual impairment in a population of older Americans. The Salisbury Eye Evaluation Study,” Archives of Ophthalmology, vol. 118, no. 6, pp. 819–825, 2000. View at Google Scholar
  4. R. Klein, B. E. Klein, S. C. Jensen, and S. M. Meuer, “The five-year incidence and progression of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 104, no. 1, pp. 7–21, 1997. View at Google Scholar
  5. H. M. Leibowitz, D. E. Krueger, L. R. Maunder et al., “The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975,” Survey of Ophthalmology, vol. 24, supplement 1, pp. 335–610, 1980. View at Google Scholar
  6. E. W. M. Ng, D. T. Shima, P. Calias, E. T. Cunningham Jr., D. R. Guyer, and A. P. Adamis, “Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease,” Nature Reviews Drug Discovery, vol. 5, no. 2, pp. 123–132, 2006. View at Publisher · View at Google Scholar
  7. J. S. Heier, A. N. Antoszyk, P. R. Pavan et al., “Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study,” Ophthalmology, vol. 113, no. 4, pp. 633–642, 2006. View at Publisher · View at Google Scholar
  8. S. Michels and P. J. Rosenfeld, “Treatment of neovascular age-related macular degeneration with Ranibizumab/LucentisTM,” Klinische Monatsblätter für Augenheilkunde, vol. 222, no. 6, pp. 480–484, 2005. View at Publisher · View at Google Scholar
  9. S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus, and A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 112, no. 6, pp. 1035–1047, 2005. View at Publisher · View at Google Scholar
  10. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar
  11. C. Bonne, “PPAR γ: a novel pharmacological target against retinal and choroidal neovascularization,” Journal Français d'Ophtalmologie, vol. 28, no. 3, pp. 326–330, 2005. View at Publisher · View at Google Scholar
  12. F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O'Connell, “Evolution of peroxisome proliferator-activated receptor agonists,” The Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007. View at Publisher · View at Google Scholar
  13. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
  14. D. Auboeuf, J. Rieusset, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-a in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997. View at Publisher · View at Google Scholar
  15. T. Lemberger, O. Braissant, C. Juge-Aubry et al., “PPAR tissue distribution and interactions with other hormone-signaling pathways,” Annals of the New York Academy of Sciences, vol. 804, pp. 231–251, 1996. View at Publisher · View at Google Scholar
  16. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPAR? activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at Publisher · View at Google Scholar
  17. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998. View at Publisher · View at Google Scholar
  18. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors a and ? induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  19. S. W. Cousins, D. G. Espinosa-Heidmann, and K. G. Csaky, “Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization?” Archives of Ophthalmology, vol. 122, no. 7, pp. 1013–1018, 2004. View at Publisher · View at Google Scholar
  20. A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994. View at Publisher · View at Google Scholar
  21. J. Auwerx, G. Martin, M. Guerre-Millo, and B. Staels, “Transcription, adipocyte differentiation, and obesity,” Journal of Molecular Medicine, vol. 74, no. 7, pp. 347–352, 1996. View at Publisher · View at Google Scholar
  22. R. Komers and A. Vrana, “Thiazolidinediones—tools for the research of metabolic syndrome X,” Physiological Research, vol. 47, no. 4, pp. 215–225, 1998. View at Google Scholar
  23. H. Itoh, K. Doi, T. Tanaka et al., “Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor ?,” Clinical and Experimental Pharmacology and Physiology, vol. 26, no. 7, pp. 558–560, 1999. View at Publisher · View at Google Scholar
  24. J. Plutzky, “Peroxisome proliferator-activated receptors in endothelial cell biology,” Current Opinion in Lipidology, vol. 12, no. 5, pp. 511–518, 2001. View at Publisher · View at Google Scholar
  25. C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007. View at Publisher · View at Google Scholar
  26. M. Meissner, M. Stein, C. Urbich et al., “PPARa activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation,” Circulation Research, vol. 94, no. 3, pp. 324–332, 2004. View at Publisher · View at Google Scholar
  27. J. Varet, L. Vincent, P. Mirshahi et al., “Fenofibrate inhibits angiogenesis in vitro and in vivo,” Cellular and Molecular Life Sciences, vol. 60, no. 4, pp. 810–819, 2003. View at Publisher · View at Google Scholar
  28. X. R. Chen, V. C. Besson, B. Palmier, Y. Garcia, M. Plotkine, and C. Marchand-Leroux, “Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR α agonist, in traumatic brain injury,” Journal of Neurotrauma, vol. 24, no. 7, pp. 1119–1131, 2007. View at Publisher · View at Google Scholar
  29. R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, part 6, pp. 1341–1346, 2006. View at Publisher · View at Google Scholar
  30. M. Arca, S. Natoli, F. Micheletta et al., “Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy,” Free Radical Biology and Medicine, vol. 42, no. 5, pp. 698–705, 2007. View at Publisher · View at Google Scholar
  31. S. H. Han, M. J. Quon, and K. K. Koh, “Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators,” Hypertension, vol. 46, no. 5, pp. 1086–1092, 2005. View at Publisher · View at Google Scholar
  32. Z. Israelian-Konaraki and P. D. Reaven, “Peroxisome proliferator-activated receptor-α and atherosclerosis: from basic mechanisms to clinical implications,” Cardiology, vol. 103, no. 1, pp. 1–9, 2005. View at Publisher · View at Google Scholar
  33. N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998. View at Google Scholar
  34. M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 45–51, 2003. View at Publisher · View at Google Scholar
  35. P. Delerive, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001. View at Publisher · View at Google Scholar
  36. N. Ferrara and H.-P. Gerber, “The role of vascular endothelial growth factor in angiogenesis,” Acta Haematologica, vol. 106, no. 4, pp. 148–156, 2001. View at Publisher · View at Google Scholar
  37. A. D. Kulkarni and B. D. Kuppermann, “Wet age-related macular degeneration,” Advanced Drug Delivery Reviews, vol. 57, no. 14, pp. 1994–2009, 2005. View at Publisher · View at Google Scholar
  38. N. Ferrara, “The role of VEGF in the regulation of physiological and pathological angiogenesis,” EXS, no. 94, pp. 209–231, 2005. View at Google Scholar
  39. A. Kvanta, P. V. Algvere, L. Berglin, and S. Seregard, “Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor,” Investigative Ophthalmology and Visual Science, vol. 37, no. 9, pp. 1929–1934, 1996. View at Google Scholar
  40. P. F. Lopez, B. D. Sippy, H. M. Lambert, A. B. Thach, and D. R. Hinton, “Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes,” Investigative Ophthalmology and Visual Science, vol. 37, no. 5, pp. 855–868, 1996. View at Google Scholar
  41. M. Kliffen, H. S. Sharma, C. M. Mooy, S. Kerkvliet, and P. T. de Jong, “Increased expression of angiogenic growth factors in age-related maculopathy,” British Journal of Ophthalmology, vol. 81, no. 2, pp. 154–162, 1997. View at Google Scholar
  42. J. A. Wells, R. Murthy, R. Chibber et al., “Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation,” British Journal of Ophthalmology, vol. 80, no. 4, pp. 363–366, 1996. View at Publisher · View at Google Scholar
  43. V. Simorre-Pinatel, M. Guerrin, P. Chollet et al., “Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway,” Investigative Ophthalmology and Visual Science, vol. 35, no. 9, pp. 3393–3400, 1994. View at Google Scholar
  44. L. P. Aiello, J. M. Northrup, B. A. Keyt, H. Takagi, and M. A. Iwamoto, “Hypoxic regulation of vascular endothelial growth factor in retinal cells,” Archives of Ophthalmology, vol. 113, no. 12, pp. 1538–1544, 1995. View at Google Scholar
  45. A. P. Adamis, D. T. Shima, K. T. Yeo et al., “Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells,” Biochemical and Biophysical Research Communications, vol. 193, no. 2, pp. 631–638, 1993. View at Publisher · View at Google Scholar
  46. E. A. Pierce, R. L. Avery, E. D. Foley, L. P. Aiello, and L. E. H. Smith, “Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 3, pp. 905–909, 1995. View at Publisher · View at Google Scholar
  47. Y. Yokoyama, B. Xin, T. Shigeto et al., “Clofibric acid, a peroxisome proliferator-activated receptor a ligand, inhibits growth of human ovarian cancer,” Molecular Cancer Therapeutics, vol. 6, no. 4, pp. 1379–1386, 2007. View at Publisher · View at Google Scholar
  48. R. Pola, E. Gaetani, A. Flex et al., “Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors,” Journal of Molecular and Cellular Cardiology, vol. 36, no. 3, pp. 363–370, 2004. View at Publisher · View at Google Scholar
  49. T. Murata, S. He, M. Hangai et al., “Peroxisome proliferator-activated receptor-? ligands inhibit choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309–2317, 2000. View at Google Scholar
  50. F. Zandbergen and J. Plutzky, “PPARα in atherosclerosis and inflammation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 972–982, 2007. View at Publisher · View at Google Scholar
  51. R. Hogg and U. Chakravarthy, “AMD and micronutrient antioxidants,” Current Eye Research, vol. 29, no. 6, pp. 387–401, 2004. View at Publisher · View at Google Scholar